Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hooker

Showing results (161-170 of 163) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 163 results.
JAMA Internal Medicine|July 14, 2025
Clinical Decision Support System for Primary Care of Opioid Use Disorder: A Randomized Clinical TrialRebecca C Rossom, A Lauren Crain, Eric A Wright, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2008
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imagingBetty B Yao, Gin Hsieh, Anthony V Daza, et al.
JAMA Network Open|October 15, 2025
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 DiabetesRomain Neugebauer, Jaejin An, Sarah Krahe Dombrowski, et al.
Pageof 17

Showing results (161-170 of 163) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 163 results.
JAMA Internal Medicine|July 14, 2025
Clinical Decision Support System for Primary Care of Opioid Use Disorder: A Randomized Clinical TrialRebecca C Rossom, A Lauren Crain, Eric A Wright, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2008
Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imagingBetty B Yao, Gin Hsieh, Anthony V Daza, et al.
JAMA Network Open|October 15, 2025
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 DiabetesRomain Neugebauer, Jaejin An, Sarah Krahe Dombrowski, et al.
Pageof 17